2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108120
    L-162537 167027-99-8 98%
    L-162537 is a competitive human angiotensin II receptor 1 (AT1) and receptor 2 (AT2) antagonist with an IC50=1.7 nM for AT1. L-162537 inhibits Ang II-mediated vasoconstriction, blood pressure elevation and related pathological signaling pathways. L-162537 is promising for research of angiotensin II-related cardiovascular diseases such as hypertension.
    L-162537
  • HY-108136
    Bisindolylmaleimide X 131848-97-0 98%
    Bisindolylmaleimide X (Ro 31-8425, BIM-X) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM. Bisindolylmaleimide X inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X can be used for research on the immune system and cardiovascular diseases.
    Bisindolylmaleimide X
  • HY-108200
    UK-315716 197077-52-4 98%
    UK-315716 is an NMDA receptor antagonist. UK-315716 has a synergistic neuroprotective effect. UK-315716 can be used for research on neurological diseases such as stroke and headache.
    UK-315716
  • HY-108248
    KU-32 956498-70-7 98%
    KU-32 is a novel, novobiocin-based Hsp90 inhibitor that can protect against neuronal cell death.
    KU-32
  • HY-108282
    (S)-Trimetoquinol hydrochloride 18559-59-6 98%
    (S)-Trimetoquinol hydrochloride (Compound 1) is a apotent, nonselective, nonclassical β-adrenergic agonist and nonprostanoid thromboxane A2/prostaglandin H2 antagonist. (S)-Trimetoquinol hydrochloride can be used for research of neurological and cardiovascular disease.
    (S)-Trimetoquinol hydrochloride
  • HY-108291
    Propatyl nitrate 2921-92-8 98%
    Propatyl nitrate is a coronary vasodilator. Propatyl nitrate is also a nitric oxide donor. Propatyl nitrate can be used in research on cardiovascular and cerebrovascular diseases such as acute angina attacks.
    Propatyl nitrate
  • HY-108303
    Neridronate sodium 80729-79-9 98%
    Neridronate sodium is a bisphosphonate. Bisphosphonates initiate the Apoptotic process. Neridronate sodium reduces the levels of bone resorption, bone turnover markers, the degree of back pain, and the risk of fractures. Neridronate sodium inhibits capillary tube formation. Neridronate sodium itself has weak anticancer activity, but liposomal encapsulation enhances this activity. Neridronate sodium can be used in research related to demineralizing metabolic bone diseases, thalassemia-associated osteoporosis, chronic inflammatory diseases, cancer, and osteogenesis imperfecta.
    Neridronate sodium
  • HY-108304
    Prajmalium bitartrate 2589-47-1 98%
    Prajmalium (bitartrate) (Prajmaline bitartrate) is an antiarrhythmic agent that plays an important role in angina pectoris.
    Prajmalium bitartrate
  • HY-108306
    Moprolol 5741-22-0 98%
    Moprolol ((±)-Moprolol) is an beta-adrenergic receptor blocker, which can be used for research in essential hypertension.
    Moprolol
  • HY-108502
    KC 12291 hydrochloride 181936-98-1 98%
    KC 12291 hydrochloride is an orally active blocker of voltage-gated sodium channel (VGSC). KC 12291 hydrochloride reduces the amplitude of sustained Na+ current to exert antiischemic activity. KC 12291 hydrochloride has significant cardioprotective effect in vitro and in vivo.
    KC 12291 hydrochloride
  • HY-108555
    FR-171113 173904-50-2 98%
    FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC50 of 0.29 μM..
    FR-171113
  • HY-108556
    RWJ-56110 252889-88-6 98%
    RWJ-56110 is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4. RWJ-56110 inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), quite selective relative to U46619 (HY-108566). RWJ-56110 inhibits angiogenesis and blocks the formation of new vessels in vivo. RWJ-56110 induces cell apoptosis.
    RWJ-56110
  • HY-108564
    L 655240 103253-15-2 98%
    L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders.
    L 655240
  • HY-108572
    S26948 353280-43-0 98%
    S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC50=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ.
    S26948
  • HY-108582
    Y-27152 127408-30-4 98%
    Y-27152, a proagent of the KATP (Kir6) channel opener Y-26763, is a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
    Y-27152
  • HY-108814
    Ecallantide 460738-38-9 98%
    Ecallantide (DX-88) is a specific plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide can be used to prevent acute attacks of angioedema.
    Ecallantide
  • HY-108864
    Epoetin alfa 113427-24-0 98%
    Epoetin alfa (Epogen) is a recombinant human erythropoietin whose amino acid sequence and biological activity are identical to those of endogenous erythropoietin (EPO). Epoetin alfa is a direct agonist of the EPO receptor (EPOR) on the surface of erythroid progenitor cells, and promotes the production and maturation of red blood cells. Epoetin alfa can be used for research on myelodysplastic syndrome-related anemia and hematological malignancies.
    Epoetin alfa
  • HY-108942
    ASP5854 851087-60-0 98%
    ASP5854 is an orally active, blood-brain barrier permeable adenosine A1/A2a dual receptor antagonist. ASP5854 blocks receptor activity and agonist-induced intracellular calcium elevation, and exhibits the characteristic of slow dissociation from striatal A2a receptors in primates. ASP5854 reverses catalepsy, enhances cognitive ability, improves motor function and exerts neuroprotective effects, while also alleviating dyskinesia and increasing contralateral turning behavior. ASP5854 is mainly used in studies related to ischemic stroke and Parkinson's disease.
    ASP5854
  • HY-108982
    UK 55444 97290-20-5 98%
    UK 55444 is a calcium antagonist. UK 55444 has coronary vasodilator activity.
    UK 55444
  • HY-108997
    Palonidipine 96515-73-0 98%
    Palonidipine is a calcium antagonist which is potential for the therapy of angina-pectoris and hypertension.
    Palonidipine
Cat. No. Product Name / Synonyms Application Reactivity